Dihomo-γ-linolenic acid

Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system[1][2][3].

Product Specifications

CAS Number

[1783-84-2]

Product Name Alternative

DGLA; all-cis-8,11,14-Eicosatrienoic acid

UNSPSC

12352211

Hazard Statement

H227, H302

Target

Endogenous Metabolite

Type

Natural Products

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/_8Z,11Z,14Z_-Icosa-8,11,14-trienoic_acid.html

Concentration

326.28 mM * 50 μL in Ethanol

Purity

99.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(O)=O

Molecular Formula

C20H34O2

Molecular Weight

306.48

Precautions

H227, H302

References & Citations

[1]Wang X, et al. Multiple roles of dihomo-γ-linolenic acid against proliferation diseases. Lipids Health Dis. 2012 Feb 14;11:25.|[2]Gallagher H, et al. Dihomo-γ-linolenic acid inhibits several key cellular processes associated with atherosclerosis. Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865 (9) :2538-2550.|[3]Yang X, et al. Dihomo-γ-linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA. Redox Biol. 2019 Jan;20:236-246.